Afirma Molecular Testing: Unique Situations and New Prognostic Development

Written by The Life Science Feed Editorial Team · Published 14 June 2026 · Edited by Mara Voss

The management of thyroid nodules with indeterminate cytology presents a clinical challenge, often leading to diagnostic surgeries for benign lesions. Molecular testing, such as Afirma, aims to reduce unnecessary procedures by providing a more definitive risk assessment.1 Recent developments presented at endo 2026 highlight its utility in specific clinical scenarios and introduce new prognostic markers for enhanced patient stratification.

KEY TAKEAWAYS

- The Pivot: Afirma molecular testing now incorporates new prognostic markers, expanding its utility beyond initial diagnostic stratification.
- The Data: Specific data points for new markers were not provided in the prompt, but the principle is enhanced risk assessment.
- The Action: Clinicians should consider Afirma testing in indeterminate thyroid nodules, particularly in unique clinical contexts, and integrate new prognostic information for refined patient management.

Thyroid nodules are common, with a significant proportion presenting with indeterminate cytology following fine-needle aspiration (FNA). The Bethesda System for Reporting Thyroid Cytopathology categories III (atypia of undetermined significance or follicular lesion of undetermined significance, AUS/FLUS) and IV (follicular neoplasm or suspicious for follicular neoplasm, FN/SFN) represent this indeterminate group. Historically, these categories often necessitated diagnostic surgery, such as lobectomy, to rule out malignancy. However, a substantial number of these surgically resected nodules prove to be benign, exposing patients to surgical risks and costs without therapeutic benefit.

Afirma molecular testing (Veracyte, Inc.) was developed to address this diagnostic gap. It analyzes gene expression classifiers (GEC) from FNA samples to identify benign nodules within the indeterminate categories, thereby potentially reducing the rate of diagnostic surgeries. The initial Afirma GEC assay was designed to classify nodules as either benign or suspicious. A benign result indicates a low probability of malignancy, allowing for surveillance rather than immediate surgery. A suspicious result suggests a higher probability of malignancy, supporting a recommendation for surgical intervention.

The prevalence of thyroid nodules is high, with palpation detecting nodules in 4-7% of the adult population and ultrasound identifying them in up to 68% of individuals. While the vast majority of these nodules are benign, approximately 5-15% harbor malignancy. FNA biopsy serves as the primary diagnostic tool for evaluating thyroid nodules, but its effectiveness is limited by the indeterminate categories, which account for 15-30% of all FNA results. This diagnostic ambiguity creates a clinical dilemma, balancing the imperative to diagnose cancer early with the desire

to avoid unnecessary invasive procedures for benign disease. Molecular testing platforms like Afirma aim to refine this balance by providing additional objective data.

Expanding Utility and Prognostic Development

The utility of Afirma testing extends to specific clinical situations where traditional cytological assessment may be particularly challenging or where patient factors influence management decisions. These unique situations can include nodules with equivocal cytological features, multifocal nodules, or nodules in patients with a history of radiation exposure. In such cases, the objective molecular data provided by Afirma can offer additional clarity, guiding clinicians toward more informed management strategies. For instance, a benign Afirma result in a patient with a history of head and neck radiation, where the risk of malignancy is generally elevated, could still support a conservative approach, avoiding unnecessary surgery.

The methodology behind Afirma involves extracting RNA from FNA samples. The initial GEC assay utilizes a proprietary algorithm to analyze the expression levels of a panel of genes. This gene expression profile is then compared to a reference database of known benign and malignant thyroid nodules. The output classifies the nodule as either benign or suspicious. A key aspect of the GEC is its high negative predictive value (NPV), meaning a benign result reliably indicates a low probability of malignancy. This characteristic allows clinicians to confidently recommend active surveillance for patients with benign GEC results, thereby reducing the need for diagnostic surgery. Conversely, a suspicious GEC result, while not definitively diagnostic of malignancy, significantly increases the pre-test probability of cancer, supporting surgical evaluation.

Recent advancements, as discussed at endo 2026, include the development of new prognostic markers within the Afirma platform. These markers are intended to provide more granular risk stratification for nodules that are classified as suspicious by the initial GEC. While the primary GEC focuses on distinguishing benign from suspicious, the new prognostic developments aim to differentiate between low-risk and high-risk malignancies, or to predict the aggressiveness of a detected cancer. This enhanced prognostic information could influence the extent of initial surgery (e.g., lobectomy versus total thyroidectomy) or guide decisions regarding adjuvant therapies and surveillance intensity. For example, a suspicious nodule with molecular features indicating a low-risk, indolent malignancy might be managed with a less aggressive surgical approach compared to a suspicious nodule with markers suggesting a more aggressive variant of thyroid cancer. This evolution in molecular testing moves beyond a simple benign/suspicious dichotomy to offer a more nuanced understanding of a nodule's biological potential, aligning management with the specific risk profile of the patient's disease.

Despite its utility, Afirma testing has limitations. It requires an adequate FNA sample for RNA extraction, and insufficient samples can lead to indeterminate molecular results. Furthermore, while the GEC has a high NPV, its positive predictive value (PPV) for malignancy is lower, meaning a suspicious result does not guarantee cancer. This necessitates further surgical evaluation for suspicious cases. The cost of molecular testing also represents a consideration in healthcare resource allocation. However, the potential for reducing unnecessary surgeries and their associated morbidity and costs often outweighs the direct cost of the test, particularly in patient populations with a high prevalence of indeterminate nodules.

CLINICAL IMPLICATIONS

The integration of Afirma molecular testing, particularly with its evolving prognostic capabilities, represents a significant refinement in the management algorithm for indeterminate thyroid nodules. For clinicians, this means a more precise tool for risk stratification, potentially reducing the number of patients undergoing diagnostic surgery for benign disease. The challenge lies in judiciously applying this technology, understanding its limitations, and interpreting results within the broader clinical context, including patient comorbidities and preferences. It is not a replacement for clinical judgment but an adjunct that demands careful consideration.
From a patient perspective, the benefit is clear: fewer unnecessary surgeries, reduced surgical morbidity, and potentially less anxiety associated with diagnostic uncertainty. However, the cost of molecular testing remains a factor, and equitable access to these advanced diagnostics is a continuing concern. As these tests become more sophisticated, ensuring that patients understand the implications of both benign and suspicious results, including the new prognostic data, will be paramount for informed decision-making.
For the industry, the continuous development of molecular assays like Afirma underscores the drive towards personalized medicine in endocrinology. Companies like Veracyte are expanding their portfolios to offer not just diagnostic clarity but also prognostic insights, which could influence treatment pathways and potentially reduce healthcare costs associated with overtreatment. The market will likely see further competition and innovation in this space, pushing for even greater accuracy and broader applicability of molecular markers in thyroid cancer management.

EDITORIAL & AI STANDARDS
AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Vardarli I, et al. Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis. Endocr Connect. 2024;13(7). doi:10.1530/EC-24-0170
2. 2. Silaghi CA, et al. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:649522. doi:10.3389/fendo.2021.649522
3. 3. Liu Y, et al. The Diagnostic Performance of Afirma Gene Expression Classifier for the Indeterminate Thyroid Nodules: A Meta-Analysis. Biomed Res Int. 2019;2019:7150527. doi:10.1155/2019/7150527
4. 4. Vuong HG, et al. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis. Cancer Cytopathol. 2021;129(3):182-189. doi:10.1002/cncy.22332
5. 5. Endo M, et al. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules. Thyroid. 2019;29(8):1115-1124. doi:10.1089/thy.2018.0733
6. 6. Yang Z, et al. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology. J Am Soc Cytopathol. 2022;11(2):74-78. doi:10.1016/j.jasc.2021.07.002
7. 7. Wei S, et al. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience. Cancer Cytopathol. 2019;127(11):720-724. doi:10.1002/cncy.22188
8. 8. Gortakowski M, et al. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules. Thyroid. 2021;31(9):1376-1382. doi:10.1089/thy.2020.0801
9.

9. Vora A, et al. Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience. Otolaryngol Head Neck Surg. 2020;162(5):634-640. doi:10.1177/0194599820911718

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com